Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH5YQ3)

Drug Name

Sugemalimab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25	Approved in China	[1]
Extranodal NK/T-cell Lymphoma	2A90.6	Phase 3	[2]

Cross-matching ID

TTD Drug ID: DMH5YQ3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[4]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[5]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[6]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[7]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[8]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[9]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[11]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[12]
A167	DME00MM	Nasopharyngeal carcinoma	2B6B	Phase 3	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[3]

------------------------------------------------------------------------------------

References

1	Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
2	ClinicalTrials.gov (NCT05700448) A Phase III, Randomized, Double-Blind, Multicenter Study of Sugemalimab (CS1001) Plus PGemOx Regimen Versus Placebo Plus PGemOx for Subjects With Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (R/R ENKTL). U.S.National Institutes of Health.
3	Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
4	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
7	ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
9	Clinical pipeline report, company report or official report of Alphamab Oncology.
10	National Cancer Institute Drug Dictionary (drug id 740856).
11	Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
12	GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.
13	Clinical pipeline report, company report or official report of Klus Pharma